Dhoot Nilu Malpani, Kumar Vinay, Shinagare Atul, Kataki Amal Chandra, Barmon Debabrata, Bhuyan Utpal
Department of Radiology, Dr B Barooah Cancer Institute, Guwahati, India.
J Med Imaging Radiat Oncol. 2012 Feb;56(1):58-65. doi: 10.1111/j.1754-9485.2011.02333.x.
To evaluate carcinoma of the cervix using magnetic resonance imaging (MRI), correlate with clinical approach of International Federation of Gynecology and Obstetrics (FIGO) staging system and to study the impact of MRI findings on patient management.
Pathologically confirmed, 75 cases of carcinoma cervix referred to our institute from April 2007 to March 2008 were prospectively studied. Clinical FIGO stage was assigned to each patient by gynaecologists blinded to MRI findings. MRI stage (based on FIGO and TNM) was allotted by radiologists blinded to clinicopathological details. For patients who were operated, histopathological stage was taken as gold standard. For patients who were not operated, gynaecologists decided on a gold standard stage based on all available clinical and imaging data. MR staging was correlated with FIGO staging, with focus on significant alterations in treatment strategy caused due to MRI findings.
MRI staging had an accuracy of 89.3% (67/75), while clinical FIGO staging had 61.3% (46/75) accuracy. MRI staging and FIGO staging concurred in 65.6% of the patients and differed in 34.4% of the patients. In about 30.6% (23/75) of the patients, there were relevant additional MRI findings not suspected clinically. The common significant MRI findings were detection of pelvic lymphadenopathy and clinically unsuspected bowel/bladder invasion. The management protocol was significantly altered in 86.9% (20/23) of the patients with additional MRI findings constituting 26.6% (20/75) of the total population.
MRI is highly accurate in evaluating carcinoma of the cervix. MRI findings significantly altered therapeutic decisions in 26.6% of the patients. MRI should be considered prior to treatment planning in every patient.
利用磁共振成像(MRI)评估宫颈癌,将其与国际妇产科联盟(FIGO)分期系统的临床方法相关联,并研究MRI结果对患者治疗管理的影响。
对2007年4月至2008年3月转诊至我院的75例经病理证实的宫颈癌患者进行前瞻性研究。由对MRI结果不知情的妇科医生为每位患者确定临床FIGO分期。由对临床病理细节不知情的放射科医生确定MRI分期(基于FIGO和TNM)。对于接受手术的患者,组织病理学分期被视为金标准。对于未接受手术的患者,妇科医生根据所有可用的临床和影像数据确定金标准分期。将MR分期与FIGO分期相关联,重点关注因MRI结果导致的治疗策略的显著改变。
MRI分期的准确率为89.3%(67/75),而临床FIGO分期的准确率为61.3%(46/75)。MRI分期和FIGO分期在65.6%的患者中一致,在34.4%的患者中不同。在约30.6%(23/75)的患者中,存在临床上未怀疑的相关MRI额外发现。常见的重要MRI发现是盆腔淋巴结病的检测以及临床上未怀疑的肠道/膀胱侵犯。在有额外MRI发现的患者中,86.9%(20/23)的患者治疗方案发生了显著改变,占总人群的26.6%(20/75)。
MRI在评估宫颈癌方面高度准确。MRI结果在26.6%的患者中显著改变了治疗决策。在对每位患者进行治疗规划之前,应考虑进行MRI检查。